(Q43951943)

28 November 2017

title

Brazilian Consensus on second-generation antipsychotics and metabolic disorders (English)

1 reference

28 November 2017

5

1 reference

28 November 2017

Clarissa Severino Gama

2

object named as

Clarissa Gama

1 reference

28 November 2017

Helio Elkis

1

1 reference

28 November 2017

Henrique Suplicy

3

1 reference

28 November 2017

Marcos Tambascia

4

1 reference

28 November 2017

Ruy Lyra

6

1 reference

28 November 2017

Saulo Cavalcante

7

1 reference

28 November 2017

Walter Minicucci

8

1 reference

28 November 2017

language of work or name

non-English

0 references

publication date

1 March 2008

1 reference

Brazilian Journal of Psychiatry

28 November 2017

published in

1 reference

28 November 2017

volume

30

1 reference

28 November 2017

issue

1

1 reference

28 November 2017

page(s)

77-85

1 reference

Consensus development conference on antipsychotic drugs and obesity and diabetes

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Guidelines for healthy weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Increasing prevalence of the metabolic syndrome among u.s. Adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Emerging epidemic of type 2 diabetes in youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Economic costs of diabetes in the US in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Physical consequences of schizophrenia and its treatment: the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Mortality in a cohort of patients with schizophrenia: a record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Causes of the excess mortality of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Body weight gain induced by antipsychotic drugs: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

The Metabolic Syndrome in Patients With Severe Mental Illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462008000100014

10.1590/S1516-44462008000100014

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference